Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

Publikation

Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

Wissenschaftlicher Artikel/Review - 05.10.2023

Spiera Robert F, Unizony Sebastian, Warrington Kenneth J, Sloane Jennifer, Giannelou Angeliki, Nivens Michael C, Akinlade Bolanle, Wong Wanling, Bhore Rafia, Lin Yong, Buttgereit Frank, Devauchelle-Pensec Valérie, Rubbert-Roth Andrea, Yancopoulos George D, Marrache Frederic, Patel Naimish, Dasgupta Bhaskar, SAPHYR Investigators

Zitation

Spiera R, Unizony S, Warrington K, Sloane J, Giannelou A, Nivens M, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos G, Marrache F, Patel N, Dasgupta B, SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med 2023; 389:1263-1272.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

N Engl J Med 2023; 389

Veröffentlichungsdatum

05.10.2023

eISSN (Online)

1533-4406

Seiten

1263-1272

Kurzbeschreibung/Zielsetzung

More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in the treatment of polymyalgia rheumatica. Sarilumab, a human monoclonal antibody, binds interleukin-6 receptor α and efficiently blocks the interleukin-6 pathway.